14 results about "Tumor Cell Migration" patented technology

The invention discloses application of a tripterygium wilfordii exosome in preparation of an anti-cervical cancer medicine and a tumor angiogenesis inhibiting medicine, and relates to the field of biological medicine. The medicinal plant exosome derived from tripterygium wilfordii is successfully separated, and it is proved that the medicinal plant exosome can regulate related pathways through delivery of functional nucleic acid molecules to inhibit proliferation and migration of cervical cancer cells and promote active oxygen related apoptosis so as to be used for tumor treatment. The tripterygium wilfordii exosome can further act on vascular endothelial cells in a tumor microenvironment, the migration function of Hela cells is inhibited, and then the effect of resisting cell proliferation in the tumor microenvironment is achieved. The tripterygium wilfordii exosome has the advantages of being simple in preparation method, remarkable in tumor growth resistance and tumor cell migration inhibition effect, good in biocompatibility, high in delivery efficiency and the like, and can be used as a novel nano-drug for tumor treatment.

The present disclosure relates to agents, such as binding proteins, that bind to vascular CD93 wherein binding of the agents to CD93 results in one or more of i) inhibition of perivascular tumor cell migration, ii) inhibition of tumor cell invasion, and iii) inhibition of tumor cell proliferation. The agent or binding protein, nucleic acid molecule or pharmaceutical composition thereof can be used in medical treatment, such as cancer therapy. The binding proteins may also be used to engineer cells to express chimeric antigen receptors having binding proteins of the disclosure as antigen binding domains.

The application discloses an affinity peptide targeting human CD81 protein and application thereof. The amino acid sequence of the affinity peptide provided by the application is shown as SEQ ID NO: 7. The affinity peptide provided by the application has high affinity and high selectivity with a small loop fragment of an extracellular CD81 protein, can recognize and combine with the CD81 protein in free and living cells, can be used for high-sensitivity detection and in-situ imaging of the CD81 protein, and can be further used as a selective inhibitor of a migration process of tumor cells expressing the CD81 protein. The affinity peptide provided by the application can specifically target and recognize the CD81 protein, is a specific probe for analysis and detection of the CD81 protein and functional research, and has application prospects in detection of diseases such as malignant tumors and development of targeted drugs. The application has important application value.

The invention discloses a composition for treating cancer, which belongs to the field of traditional Chinese medicine compound preparations, is obtained by optimizing a traditional Chinese medicine classical prescription lily Golden Decoction, is prepared from 5g of lily, 6g of dried rehmannia root, 9g of prepared rehmannia root, 5g of dwarf lilyturf tuber, 5g of figwort root, 5g of bulbus fritillariae cirrhosae, 5g of platycodon root, 5g of Chinese angelica, 5g of white paeony root and 5g of honey-fried licorice root, and is prepared by the following steps: uniformly mixing, adding 440mL (8 times of volume) of deionized water, and soaking for 0.5 hour; boiling with strong fire, decocting with slow fire for 1 hour, filtering and collecting decoction; adding 330mL (6 times of volume) of deionized water into the filter residues, repeatedly decocting for 1 hour, filtering and collecting decoction; combining the two decoctions, concentrating in a water bath to 55mL, and refrigerating at 4 DEG C to obtain the traditional Chinese medicine. By inhibiting an EGFR / PI3K / AKT signal channel, reducing the phosphorylation level of key protein of the channel, promoting tumor cell apoptosis and inhibiting tumor cell migration and invasion, NSCLC tumor growth is remarkably inhibited, paclitaxel drug resistance is reversed, and a new traditional Chinese medicine compound preparation and a treatment strategy are provided for cancer treatment.

This invention relates to an animal model of mediastinal lymph node metastasis in lung cancer and its construction method. The core of this invention lies in the precise intrapulmonary in situ microinjection technique to directly implant human lung cancer cells into the lung parenchyma of immunodeficient mice. Utilizing the natural lymphatic drainage pathway of the lung tissue, tumor cells are induced to migrate to the mediastinal lymph nodes, thus successfully constructing a complete metastasis chain model from the primary tumor to regional lymph nodes. This model can more realistically simulate the microenvironment and process of lung cancer lymph node metastasis, and is suitable for metastasis mechanism research, drug evaluation, and the development of personalized treatment strategies, possessing high translational medicine value.

The invention belongs to the technical field of cell mechanics, and particularly relates to a single cell dynamic mechanical loading system based on magnetic beads and a bidirectional static magnetic field and a force regulation and control method. The invention provides a single cell dynamic mechanical loading system based on magnetic beads and a bidirectional static magnetic field and a force regulation and control method. The system is composed of a magnetic field system module, a dynamic regulation and control module and a cell stress feedback module. Through the system, single-cell-level pulling / pressing two-way mechanical stimulation is achieved for the first time, magnetic bead concentration-magnetic field direction cooperative adjustment is achieved, and limitation of a traditional multi-cell loading mechanical mode is broken through; the system is used for carrying out mechanical regulation and control on single cells, can be used for single cell mechanical response research (such as stem cell differentiation and tumor cell migration), drug screening (detecting the influence of drugs on cell mechanical characteristics) and construction of a dynamic mechanical microenvironment in tissue engineering, and has a good application prospect.

The invention discloses a circulating exosome miRNA marker combination for colorectal cancer liver metastasis diagnosis, a detection method and a kit. The marker combination is composed of hsamiR-210-3p with up-regulated expression, hsamiR-25-3p with up-regulated expression and hsamiR-200b-3p with down-regulated expression, and the hsamiR-210-3p, the hsamiR-25-3p and the hsamiR-200b-3p respectively correspond to three different disease mechanisms, namely tumor cell migration, microenvironment formation before metastasis and an epithelial-mesenchymal transition process; a comprehensive detection model is constructed on the basis; the invention further provides an exosome miRNA detection method capable of eliminating system differences and technical errors. The invention further provides a kit containing the three miRNA specific primers and an external reference. The kit is applied to early diagnosis and dynamic disease course monitoring of colorectal cancer liver metastasis. An independent clinical queue verifies that the scheme has relatively high diagnosis efficiency on colorectal cancer liver metastasis, and the accuracy and specificity of diagnosis are effectively improved.

This invention relates to the field of biomedical technology, specifically to the application of UL16-binding protein 2 (ULBP2) as a biomarker for colorectal cancer (CRC). Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of ULBP2 expression. The results showed that ULBP2 was significantly highly expressed in CRC tissues, and the high expression level was significantly associated with a shortened overall survival (OS), demonstrating its good diagnostic and prognostic value. Functional experiments showed that knockdown of the ULBP2 gene significantly reduced the survival and proliferation of HCT-8 and LoVo cells, and effectively inhibited tumor cell migration, indicating that ULBP2 inhibitors have good application prospects in the development of colorectal cancer therapeutics. This invention provides a new biomarker and therapeutic target for the diagnosis, prognosis, and treatment of colorectal cancer.

The invention discloses an early prediction biomarker and a prediction model for colorectal cancer liver metastasis, the biomarker is an exosome RNA derived from plasma, and the biomarker comprises at least one of HRC, MAP1B, ALPK3, ADAMTS5, ADAMTS4, KATNAL2, LSMEM1, PALM3, SPCS2P4, PRKAR1AP1, OR2R1P, SMIM20, AC007319.1, AL590560.1 and AC100810.3. The marker with liver metastasis specificity is identified in colorectal cancer exosome RNA, the effect of the marker in tumor cell migration is defined through cross validation, the marker can be used for predicting the risk of liver metastasis, potential molecular targets can be provided for follow-up targeted intervention research, and the application value of the marker is expanded.

The application discloses application of an ethyl acetate extraction part of Rhus copallinum L. roots in preparation of a medicine for treating breast cancer. In the application, the ethyl acetate extraction part of Rhus copallinum L. roots is prepared by using Rhus copallinum L. roots as raw materials, 70% ethanol extraction and ethyl acetate extraction process. In vitro pharmacodynamic experiments show that the ethyl acetate extraction part of Rhus copallinum L. roots can inhibit 4T1 cell proliferation of breast cancer, block the cell cycle at the G1 phase, induce tumor cell apoptosis, and inhibit tumor cell migration; in vivo pharmacodynamic experiments further prove that the ethyl acetate extraction part of Rhus copallinum L. roots can significantly inhibit growth of a breast cancer mouse transplanted tumor, increase tumor tissue necrosis and promote tumor cell apoptosis. The application firstly uses the ethyl acetate extraction part of Rhus copallinum L. roots as the medicine for treating breast cancer, provides a new candidate medicine for clinical breast cancer treatment, and has important application value in the pharmaceutical industry.

The application belongs to the technical field of medicine, and particularly relates to a styrene acetate compound, a preparation method and application thereof. The application provides a styrene acetate compound with a structure shown in formula 1. The styrene acetate compound with the structure shown in formula 1 provided by the application can play a role of inhibiting RAC1 activity by being combined with RAC1 protein, and is suitable for treating diseases related to RAC1 protein, including Alzheimer's disease, atherosclerosis, tumor cell migration and tumor cell invasion, etc. The results of the examples also show that the styrene acetate compound with the structure shown in formula 1 provided by the application can significantly inhibit the formation of cytoskeleton of tumor cells such as breast cancer and gastric cancer, thereby playing a role of inhibiting the migration and invasion activity of tumor cells.

The invention belongs to the technical field of biological medicine and nanometer, and particularly relates to a nanometer medicine loaded with astragalus polysaccharide and a preparation method and application thereof.According to the nanometer medicine, biodegradable polylactic acid-glycolic acid copolymer serves as a carrier, astragalus polysaccharide is encapsulated through a multiple emulsion solvent evaporation method, and the nanometer medicine is prepared. The obtained nano-particles can effectively realize efficient delivery of astragalus polysaccharide, in-vitro experiments prove that the nano-drug can inhibit tumor cell migration and invasion, in a colorectal cancer tumor-bearing mouse model, the nano-drug can significantly inhibit tumor growth and activate adaptive immune response, and the nano-drug is simple and convenient in preparation method, good in safety and suitable for industrial production. And a new effective strategy is provided for immunotherapy of colorectal cancer.

The invention provides application of PCV2 in preparation of oncolytic viruses, and belongs to the technical field of biological medicines. The invention proposes that PCV2 can be used as an oncolytic virus for the first time, the PCV2 can efficiently infect various human tumor cell lines in a broad-spectrum manner, replication and filial generation virus assembly are completed in cytoplasm, and finally virus particles are released in a cell lysis or apoptosis way. The novel oncolytic virus PCV2 provided by the invention is low in human normal cell tropism and has natural tumor cell tropism. Compared with the traditional virulent oncolytic virus, the PCV2 has a mild killing effect, and mostly realizes tumor depletion death by inhibiting cell growth, limiting tumor energy supply, inhibiting tumor cell migration and invasion and other anti-tumor effects, so that the PCV2 is safer. Through xenotransplantation tumor-bearing mouse model in-vivo experiments, the PCV2 shows an obvious oncolytic effect in lung cancer and cervical cancer, and has an obvious clinical application value.

The invention discloses a polypeptide targeting PTPRE / MARCH9 interaction and application of the polypeptide in inhibition of tumor metastasis, and relates to the technical field of biological medicines, the sequence number of the polypeptide is one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4; the polypeptide inhibitor capable of accurately intervening in protein-protein interaction is designed on the basis of a newly found MARCH9 / PTPRE signal axis for the first time, and a brand new strategy and candidate molecules are provided for development of anti-tumor metastasis drugs; compared with a traditional broad-spectrum inhibitor, the polypeptide directly acts on a specific protein-protein interaction interface, potential toxic and side effects caused by global interference on an intracellular signal network are avoided, and higher selectivity is achieved; a ubiquitination experiment, an in-vitro cell migration experiment and an in-vivo animal model experiment prove that the polypeptide (especially RE-2W-4) can remarkably inhibit PTPRE ubiquitination modification, tumor cell migration and in-vivo tumor metastasis from multiple levels and multiple angles.